hepatocellular carcinoma – Page 2

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

By MedXY 09/27/2025

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy.

General Surgery news Oncology Specialties

Optimizing Treatment Selection for Hepatocellular Carcinoma: Machine Learning Guidance in Choosing Liver Transplantation versus Surgical Resection

By MedXY 09/23/2025

A machine learning model accurately stratifies patients with hepatocellular carcinoma to guide individualized selection between liver transplantation and surgical resection, improving survival outcomes while addressing donor scarcity and patient heterogeneity.

Clinical Updates Infectious Diseases news

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY 09/04/2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatments.

news Oncology Specialties

Targeting Oxytocin Receptor: A Novel Strategy Against Hepatocellular Carcinoma Using Atosiban

By MedXY 08/31/2025

Recent research identifies the oxytocin receptor (OXTR) as a critical driver of liver cancer via Hippo/YAP signaling. The FDA-approved tocolytic drug Atosiban shows promise in blocking this pathway, offering new therapeutic avenues in hepatocellular carcinoma management.

Clinical Updates General Surgery news Oncology Radiology Specialties

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.

Clinical Updates General Surgery news Oncology Specialties

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

By MedXY 08/07/2025

The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.

Clinical Updates news Oncology Specialties

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY 08/02/2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.